Companies To Watch: Mirum Pharmaceuticals
By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases
Mirum Pharmaceuticals focuses on developing two drugs with multiple indications for rare liver diseases. One of the products, Livmarli (maralixibat), entered the market in 2022 with FDA approval for treating cholestatic pruritus in Alagille syndrome (ALGS). Mirum obtained maralixibat and the other lead drug, volixibat, from Shire to spark its founding in 2018. The company has submitted maralixibat for EU approval of cholestatic liver disease in patients with ALGS as it completes the drug’s Phase 2/3 trials for progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA). It is also in late-stage development of volixibat for primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and primary biliary cholangitis (PBC).
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.